Inhibikase Therapeutics, Inc.
inhibikase.comWhat Do They Do?
Develops an oral drug candidate for people with pulmonary arterial hypertension.
10-K for FY2025, filed Mar 26, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 11, 2026
−$19.6MView ↗
- ▲ +98% (Loss)
- vs −$9.9M in Q2 FY2025
-
Aug 26, 2026
Company changes its independent auditor
CohnReznick was dismissed, and Deloitte was appointed for the fiscal year ending December 31, 2026.
Sources
8-K, filed Aug 26, 2026
On August 21, 2026, the Audit Committee appointed Deloitte & Touche LLP (“Deloitte”) as the Company’s independent registered public…View ↗
Therapeutic focus
The older report centered on Parkinson’s disease and related neurological conditions; the latest centers on pulmonary arterial hypertension.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 26, 2026We are a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease…View ↗
We are a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary…View ↗
Who Do They Compete With?
Competes with GlaxoSmithKline, Johnson and Johnson, United Therapeutics, Bayer Pharmaceuticals, Liquidia, Gilead Sciences, Merck and, Regeneron, Novartis Pharmaceuticals, Pfizer, Gossamer Bio, and Insmed
10-K for FY2025, filed Mar 26, 2026Our product candidate for treatment of PAH will compete with approved treatments as well as other therapies that may be in clinical or…View ↗
Loading...
